The US FDA has approved Galderma's Nemluvio (nemolizumab), for individuals aged 12 years and above with moderate-to-severe atopic dermatitis.
The biopharmaceutical industry faces a future full of risks and rewards. But what role will 3PL suppliers play?
New HTA statistics produced by Denmark’s Medicinrådet for 2024 have prompted GlobalData to assess evolving HTA trends in the Nordic market.
WuXi AppTec and WuXi Biologics are looking to sell off sites in the US and Europe as the prospect of the Biosecure Act is deterring potential clients.
Discover the latest advancements in small cell lung cancer through Novotech CRO’s in-depth disease analysis. Gain valuable insights into novel therapies, ongoing clinical trials, and future ...
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended Eli Lilly’s Omvoh (mirikizumab) for approval in the European Union (EU) to treat adults with ...
AbbVie has entered into a definitive agreement to acquire Nimble Therapeutics in a deal valued at $200m in cash.
Ulefnersen Sodium is an antisense oligonucleotide commercialized by Ionis Pharmaceuticals, with a leading Phase III program in Amyotrophic Lateral Sclerosis.
GCC-4001 is a cell therapy commercialized by Artiva Biotherapeutics, with a leading Phase II program in B-Cell Non-Hodgkin Lymphoma.
Mazisotine is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Diabetic Neuropathic Pain.
NBI-1076986 is a small molecule commercialized by Neurocrine Biosciences, with a leading Phase I program in Movement Disorders.